THE ROLE OF IL-17 INHIBITORS IN THE MANAGEMENT OF SEVERE PSORIASIS: LONG-TERM EFFICACY AND SAFETY

Abstract

IL-17 inhibitors have emerged as effective therapies in the management of severe psoriasis, providing robust symptom control and significant improvement in quality of life. This integrative review evaluated the long-term efficacy and safety of these biologic agents, including secukinumab, ixekizumab, and brodalumab. Data analysis revealed that these inhibitors provide high PASI 75 and PASI 90 response rates, sustained over time, with a generally favorable safety profile. Although most adverse events are mild to moderate, such as upper respiratory infections and injection site reactions, continued surveillance is necessary to manage associated risks. Treatment adherence is high due to prolonged efficacy and convenient dosing regimen, but management of adverse events and effective communication with patients are crucial to ensure therapeutic success. Directions for future research include in-depth evaluation of long-term safety and comparison of different IL-17 inhibitors with other therapeutic options.